Palvella Therapeutics, Inc. (Nasdaq: PVLA) is a clinical-stage biopharmaceutical company developing investigational topical therapies for serious, rare skin diseases and vascular malformations that currently have no FDA-approved treatments. News about Palvella often centers on progress across its QTORIN™ platform, including clinical trial milestones, regulatory designations, and pipeline expansion.
The company’s lead candidate, QTORIN™ 3.9% rapamycin anhydrous gel, is being studied in the Phase 3 SELVA trial for microcystic lymphatic malformations and in the Phase 2 TOIVA trial for cutaneous venous malformations, with additional development planned in clinically significant angiokeratomas. Updates on these programs include topline clinical results, details on trial design, and commentary from investigators and company leadership on efficacy and safety findings.
Palvella also reports news on its second product candidate, QTORIN™ pitavastatin, for disseminated superficial actinic porokeratosis, including announcements of its selection as a new QTORIN-derived therapy and plans for Phase 2 clinical evaluation. Regulatory and grant-related news, such as FDA Breakthrough Therapy, Fast Track, and Orphan Drug designations and Orphan Products Grant funding, provide additional context on how regulators view the unmet need in the company’s target indications.
Investors and observers following PVLA news can expect coverage of quarterly financial results, corporate updates, leadership appointments in areas like medical affairs and innovation, and participation in healthcare conferences. This news stream helps track how Palvella advances its investigational programs, manages its development priorities, and positions its QTORIN™ platform within the rare dermatologic disease landscape, while consistently noting that its product candidates remain investigational and unapproved.
Palvella Therapeutics (Nasdaq: PVLA) reported third-quarter results and FDA acceptance of its QTORIN rapamycin application with Priority Review. The application covers microcystic lymphatic malformations, with an FDA target action date of February 28, 2027. Palvella is preparing for a standalone U.S. launch in the first half of 2027, if approved.
Cash, cash equivalents and short-term investments totaled $236.7 million at September 30, 2026. Quarterly net loss widened to $24.643 million, or $1.70 per share, from $11.345 million, or $1.03 per share, a year earlier. Research and development and administrative expenses increased. Palvella expects fourth-quarter 2026 trial starts for cutaneous venous malformations and disseminated superficial actinic porokeratosis. Its Phase 2 angiokeratoma trial is enrolling, with results expected in the second half of 2027. Two pipeline additions are planned for the fourth quarter of 2026.
Palvella Therapeutics (Nasdaq: PVLA) management will present at the Stifel 2026 Healthcare Conference on November 10, 2026, at 9:20 a.m. ET.
A live webcast will be available in the Events and Presentations section of the company's website at www.palvellatx.com. An archived replay will remain available for approximately 90 days following the event.
Palvella Therapeutics (PVLA) will report its third quarter 2026 financial results before market open on November 5, 2026. Management will host an investor conference call at 8:30 a.m. ET that day to discuss the results and provide a corporate update. A webcast with presentation slides will be accessible through the company’s website.
Palvella Therapeutics (Nasdaq: PVLA) announced FDA acceptance and Priority Review of its application for QTORIN rapamycin to treat microcystic lymphatic malformations.
The FDA set a February 28, 2027 target action date. The application covers 3.9% rapamycin anhydrous gel. Phase 3 SELVA achieved statistical significance across all six prespecified efficacy endpoints (all p<0.001). Among participants aged 6 years and older who completed the efficacy evaluation period, 95% improved on the primary disease assessment endpoint, mLM-IGA. No drug-related serious adverse events were reported; systemic rapamycin concentrations remained below 2 ng/mL at all measured timepoints for all participants.
Palvella is preparing for a potential standalone U.S. launch in the first half of 2027, subject to FDA approval, with commercial leadership, a deployed medical science liaison team and a patient services organization established.
Palvella Therapeutics (Nasdaq: PVLA) will present QTORIN rapamycin trial results and new pediatric analyses at the PeDRA Annual Conference. The conference runs October 15–17, 2026, in Alexandria, Virginia; both posters are scheduled for October 15.
In Phase 3 SELVA, pediatric analyses highlighted improvements in overall disease severity and a blinded combined score covering lesion height, vesicle appearance, and leaking/bleeding in children with microcystic lymphatic malformations. In Phase 2 TOIVA, pediatric analyses highlighted improved overall disease severity and reduced lesion bleeding in previously treated children with cutaneous venous malformations. The posters combine previously reported trial results with new pediatric analyses. Palvella aims to develop QTORIN rapamycin as an FDA-approved therapy for both diseases, which currently have no FDA-approved therapies.
Palvella Therapeutics (PVLA) management will participate in a fireside chat at the Chardan 10th Annual Healthcare Conference on October 20, 2026.
The chat is scheduled for 1:45 p.m. ET. A live webcast will be available in the Events and Presentations section of Palvella's website, with an archived replay available for approximately 90 days following the event.
Palvella Therapeutics (PVLA) announced three posters presenting Phase 3 SELVA findings and a U.S. analysis of diagnosed DSAP patients. At Week 24, all exit-interview participants reported meaningful improvement in at least one symptom of microcystic lymphatic malformations. Among participants completing the 24-week efficacy period, 95% improved on the primary investigator assessment, including 86% rated “Much Improved” or “Very Much Improved”; 98% elected continued treatment.
A 24-participant substudy found mean systemic rapamycin exposure at least 40-fold lower than reported oral sirolimus exposure, with low, stable concentrations over 24 hours. Palvella completed its FDA application submission for QTORIN rapamycin in August 2026. Claims analysis estimated 154,986 U.S. patients diagnosed with disseminated superficial actinic porokeratosis (DSAP) during 2018–2025. Palvella anticipates starting a Phase 2 QTORIN pitavastatin trial in the fourth quarter of 2026.
Palvella Therapeutics (PVLA) received a third year of FDA grant funding for its Phase 3 QTORIN rapamycin program.
The award supports the SELVA trial and its ongoing open-label extension study of QTORIN 3.9% rapamycin anhydrous gel for microcystic lymphatic malformations. In February 2026, Palvella reported that SELVA met its primary endpoint, pre-specified key secondary endpoint and all four other secondary efficacy endpoints; all six achieved statistical significance (p<0.001). Palvella completed its New Drug Application submission in August 2026 and is preparing for a potential U.S. launch in the first half of 2027, if approved.
Niagen Bioscience (NAGE) has engaged Red Sky Partners and veteran dealmaker Martin Hendrix, Ph.D., to support advancement of its small-molecule investigational drug NB4168 and broader corporate growth and potential M&A initiatives.
Red Sky advisors Pauline Jen Ryan and Christopher Kiritsy bring decades of experience in biotechnology fundraising, drug development, commercialization, and strategic transactions. Ryan previously helped secure Kadcyla® and Sarclisa® partnerships at ImmunoGen and raise nearly $300 million through partnerships and public offerings. Kiritsy helped build Kos Pharmaceuticals into a fully integrated company that developed the Niaspan® franchise and was acquired by Abbott Laboratories for approximately $4 billion, and he serves on the board of Palvella Therapeutics (PVLA). Hendrix previously led M&A initiatives at Nestlé Health Science. NB4168 targets rare genetic diseases, with an initial focus on Ataxia Telangiectasia (A‑T), a severe childhood-onset condition with no FDA‑approved therapies.
Palvella Therapeutics (PVLA) has appointed pediatric dermatologist James R. Treat, M.D. as Chief Medical Officer, effective December 21, 2026.
Dr. Treat is a nationally recognized expert in cutaneous vascular anomalies, including microcystic lymphatic malformations, venous malformations, and angiokeratomas, and has nearly 20 years of clinical, research, and academic experience. He has been a longstanding collaborator with Palvella and a site investigator at Children’s Hospital of Philadelphia for Phase 3 SELVA and Phase 2 studies of QTORIN™ rapamycin in microcystic lymphatic malformations. As CMO, he will lead medical strategy across clinical development, medical affairs, and scientific engagement while Palvella advances QTORIN rapamycin and its rare disease pipeline.